Handelsavisen
prelaunch
Companies Healthcare 2070.SE
20
2070.SE Tadawul Pharmaceuticals

Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC

$28,98
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
8,4 %
ROE
1,1 %
Net margin
4,6 %
Debt / equity
1,01
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC is a pharmaceutical company that develops, produces, and distributes pharmaceutical products and medical appliances.

Business. Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC (2070.SE) is a Saudi Arabian pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical products. The firm is headquartered in Saudi Arabia and operates within the broader healthcare sector, specifically focusing on the pharmaceuticals industry. It is primarily listed on the Tadawul stock exchange. Detailed information regarding specific operating segments or geographic revenue breakdowns is not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
HOLD3 analysts
0 buy3 hold0 sell
Avg 12m price target31,65

Analyst recommendations

3 analysts · consensus Hold
Buy0
Hold3
Sell0
12-month price target
31,65
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Hold
3 analysts · indicative
Ownership
not yet wired
Profitability
1,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2070.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2070.SE. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC (2070.SE) is a Saudi Arabian pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical products. The firm is headquartered in Saudi Arabia and operates within the broader healthcare sector, specifically focusing on the pharmaceuticals industry. It is primarily listed on the Tadawul stock exchange. Detailed information regarding specific operating segments or geographic revenue breakdowns is not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    ### Capital Structure and Liquidity Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC has a debt-to-equity ratio of 1.01, indicating a balanced capital structure with debt and equity in near parity. The company's liquidity is assessed as medium, with a current ratio of 1.26, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. The company's operating cash flow is negative at -212.58 million SAR, and free cash flow is only 4.93 million SAR, indicating limited cash generation capacity.

    ### Profitability and Returns The company's return on equity (ROE) is 1.15%, and return on assets (ROA) is 0.39%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The operating margin is 8.36% (calculated from operating income of 31.22 million SAR on revenue of 373.49 million SAR), and the net profit margin is 4.58% (calculated from net income of 17.10 million SAR on revenue of 373.49 million SAR), both of which are modest.

    ### Segments and Geographic Exposure The company operates as a single entity without disclosed segments, and its geographic exposure is primarily within Saudi Arabia. There is no information on revenue concentration by region or product line.

    ### Growth Trajectory The company's revenue for the latest period is 373.49 million SAR. Analysts have provided a mean price target of 31.65 SAR and a median price target of 32.80 SAR, with a mean recommendation of 3.00 (Hold). There is no specific guidance on future revenue growth or earnings per share (EPS) provided in the input data.

    ### Risk Factors The company faces medium liquidity risk due to its negative net cash position after subtracting total debt. The dilution risk is assessed as low, with no significant dilution expected in the near term. The company's capital expenditures are -57.71 million SAR, indicating a net outflow, and its operating cash flow is negative, which may limit its ability to fund future growth without external financing.

    ### Recent Events There are no specific recent events, filings, or transcripts provided in the input data to indicate material changes in the company's operations or strategy.

    Key takeaways
    • The company has a balanced capital structure with a debt-to-equity ratio of 1.01.
    • ROE and ROA are below typical thresholds for strong performance in the pharmaceutical industry.
    • The company's liquidity is medium, with a current ratio of 1.26 and limited free cash flow.
    • Analysts have a neutral outlook, with a mean recommendation of 3.00 (Hold).
    • The company's operating cash flow is negative, and its free cash flow is minimal.
    • There is no significant dilution risk in the near term.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Net income surged 651.4% year-over-year to SAR 184.4 million, signaling a robust profitability recovery.

    Free cash flow improved 381.9% to SAR 204.8 million, demonstrating significant enhancement in cash generation capabilities.

    Analysts project 9.2% upside to a mean price target of SAR 31.65, suggesting undervaluation relative to current price.

    Revenue grew 4.0% CAGR over four years, providing a stable top-line foundation for future earnings expansion.

    BEAR CASE · 5

    Debt-to-equity ratio of 1.01 sits in the bottom quartile, reflecting significantly higher leverage than peers.

    Return on equity of 1.15% falls well below the cohort median of 2.92%, indicating poor capital efficiency.

    High credit risk flags suggest potential difficulties in meeting financial obligations or servicing existing debt levels.

    Cash conversion metric of -12.43 ranks in the bottom quartile, highlighting weak ability to convert earnings to cash.

    Medium liquidity risk indicates potential challenges in meeting short-term financial obligations without significant asset sales.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-03
    Q1 2026 · Quarter highlights

    Revenue SAR 423.8M, −12,6% YoY; Operating income +3,5% YoY.

    RevenueSAR 423.8M−12,6 % YoY
    Operating incomeSAR 87.5M+3,5 % YoY
    Net incomeSAR 65.1M−8,1 % YoY
    Free cash flowSAR 80.3M−2,4 % YoY
    EPS
    Operating cash flowSAR 111.4M+504,0 % YoY
    Financials
    Income statement
    RevenueSAR 423.8M
    Gross profitSAR 236.1M
    Operating incomeSAR 87.5M
    Net incomeSAR 65.1M
    Margins
    Gross margin55.7%
    Operating margin20.6%
    Net margin15.4%
    FCF margin19.0%
    Balance sheet
    Total assetsSAR 4.27B
    Total liabilitiesSAR 2.61B
    Total equitySAR 1.66B
    Cash & equivalentsSAR 0.00
    Long-term debtSAR 1.27B
    Cash flow
    Operating cash flowSAR 111.4M
    CapEx-SAR 10.7M
    Free cash flowSAR 80.3M
    SBC
    P&L flow · revenue → net income
    Revenue SAR 423.8MOperating costs SAR 336.4MTax SAR 22.4MNet income SAR 65.1M
    Highlights
    • Revenue SAR 423.8M, −12,6% YoY
    • Operating income +3,5% YoY
    • Net income −8,1% YoY
    • Free cash flow −2,4% YoY
    • Net margin 15.4%

    Valuation TTM

    Market price
    $28,98
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.48B
    Net cash
    -$1.47B
    Current ratio
    1.3
    Debt / equity
    1.0
    ROA
    0.4%
    ROE
    1.1%
    Cash conversion
    -1243.0%
    CapEx / revenue
    -15.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,86
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-21 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,86
    Revenueno estimateno estimate1,9B SAR
    Operating incomeno estimateno estimate307,2M SAR
    Full-year consensus mean (period as reported by source) · consensus in SAR. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy0
    Buy0
    Hold3
    Sell0
    Strong sell0
    12-month price target$31,65 · Median $32,80
    Low $28,00High $33,00
    Operating income · consensus307,2M SAR
    EPS surprise
    −17,3 %
    reported vs consensus · miss
    Revenue surprise
    −11,6 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$28,00
    Mean$31,65
    Median$32,80
    High$33,00
    Spot$28,98
    +9.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin8,4 %Above median
    Net Margin4,6 %Above median
    ROE1,1 %Below median
    Capex / Rev-15,4 %Bottom quartile
    D/E1,01Bottom quartile
    Cash Conv-12,43Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC Market data — financials · 2026-05-26
    • Saudi Pharmaceutical Industries and Medical Appliances Corp SPIMACO ADDWAEIH SJSC Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2070.SECanonical
    Tadawul · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-05-03 06:43 UTCEARNINGSQuarterly results — Q1 2026 Revenue SAR 423.8M · Net SAR 65.1M
    2026-03-31 12:36 UTCEARNINGSQuarterly results — Q4 2025 Revenue SAR 405.8M · Net SAR 38.8M
    2026-03-31 12:36 UTCEARNINGSAnnual results — FY 2026 Revenue SAR 1.71B · Net SAR 184.4M
    2025-11-02 13:36 UTCEARNINGSQuarterly results — Q3 2025 Revenue SAR 415.3M · Net SAR 42.1M
    2025-08-03 07:35 UTCEARNINGSQuarterly results — Q2 2025 Revenue SAR 400.8M · Net SAR 32.6M
    2025-05-12 12:41 UTCEARNINGSQuarterly results — Q1 2025 Revenue SAR 484.8M · Net SAR 70.8M
    2025-03-27 13:31 UTCEARNINGSQuarterly results — Q4 2024 Revenue SAR 386.2M · Net SAR -36.2M
    2025-03-27 13:31 UTCEARNINGSAnnual results — FY 2025 Revenue SAR 1.68B · Net SAR 24.5M
    2024-11-11 05:15 UTCEARNINGSQuarterly results — Q3 2024 Revenue SAR 447.3M · Net SAR -11.0M
    2024-08-11 14:28 UTCEARNINGSQuarterly results — Q2 2024 Revenue SAR 373.5M · Net SAR 17.1M
    2024-03-31 13:13 UTCEARNINGSAnnual results — FY 2024 Revenue SAR 1.66B · Net SAR -50.7M
    2023-03-23 06:04 UTCEARNINGSAnnual results — FY 2023 Revenue SAR 1.42B · Net SAR -165.1M
    2022-03-24 13:08 UTCEARNINGSAnnual results — FY 2022 Revenue SAR 1.46B · Net SAR 26.5M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage